menu
    • menu
    [{"orgOrder":0,"company":"Centaur Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Diperoxochloric Acid","moa":"","graph1":"Podiatry","graph2":"Approved","graph3":"Centaur Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"Centaur Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Centaur Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MiMedx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Human Amnion Membrane Allograft","moa":"","graph1":"Podiatry","graph2":"Approved","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"MiMedx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MiMedx \/ Not Applicable"},{"orgOrder":0,"company":"MiMedx","sponsor":"Gunze Medical Limited","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Human Amnion Membrane Allograft","moa":"","graph1":"Podiatry","graph2":"Approved","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"MiMedx \/ Gunze Medical Limited","highestDevelopmentStatusID":"12","companyTruncated":"MiMedx \/ Gunze Medical Limited"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Citric Acid","moa":"","graph1":"Podiatry","graph2":"Approved","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"Kane Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kane Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Edetate Calcium Disodium","moa":"","graph1":"Podiatry","graph2":"Approved","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kane Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Edetate Calcium Disodium","moa":"","graph1":"Podiatry","graph2":"Approved","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"Kane Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kane Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Edetate Calcium Disodium","moa":"","graph1":"Podiatry","graph2":"Approved","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"Kane Biotech \/ NRC IRAP","highestDevelopmentStatusID":"12","companyTruncated":"Kane Biotech \/ NRC IRAP"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Qatar Datamation Systems","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Polyhexanide","moa":"","graph1":"Podiatry","graph2":"Approved","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"Kane Biotech \/ Qatar Datamation Systems","highestDevelopmentStatusID":"12","companyTruncated":"Kane Biotech \/ Qatar Datamation Systems"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Polyhexanide","moa":"","graph1":"Podiatry","graph2":"Approved","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"Kane Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kane Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"BioStem Technologies","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Polyhexanide","moa":"","graph1":"Podiatry","graph2":"Approved","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"Kane Biotech \/ BioStem Technologies","highestDevelopmentStatusID":"12","companyTruncated":"Kane Biotech \/ BioStem Technologies"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kane Biotech

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide,Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Study Phase : Approved

                            Sponsor : BioStem Technologies

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Kane Biotech Changes US Partner for Revyve™ Antimicrobial Wound Gel Distribution

                            Details : BioStem Technologies will acquire exclusive US distribution rights for revyve from ProgenaCare Global.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 27, 2024

                            Lead Product(s) : Polyhexanide,Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved

                            Sponsor : BioStem Technologies

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kane Biotech

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide,Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Study Phase : Approved

                            Sponsor : Qatar Datamation Systems

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kane Biotech Signs Deal with Qatar Datamation For Wound Gel Distribution

                            Details : The agreement aims for the distribution of revyve antimicrobial wound gel indicated for diabetic foot ulcers, in the Qatar wound care market.

                            Product Name : Revyve

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 28, 2024

                            Lead Product(s) : Polyhexanide,Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved

                            Sponsor : Qatar Datamation Systems

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kane Biotech

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Study Phase : Approved

                            Sponsor : NRC IRAP

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Kane Biotech Receives Funding Support to Expand the Revyve Antimicrobial Wound Gel Family

                            Details : The funding will support the development of three additional products to build on Kane Biotech’s revyve Antimicrobial Wound Gel technology for management of ulcers.

                            Product Name : Revye

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 13, 2024

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved

                            Sponsor : NRC IRAP

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kane Biotech

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kane Biotech Receives FDA Approval to Increase Dosage of Revyve™ Wound Gel

                            Details : Revyve Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), burns, partial & full thickness wounds for adult populations.

                            Product Name : Revye

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 23, 2024

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kane Biotech

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kane Biotech and ProgenaCare Global Launch Newly Rebranded Revyve™ Antimicrobial Wound Gel at Advanced Wound...

                            Details : revyve™ Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult po...

                            Product Name : Revye

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 02, 2023

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kane Biotech

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EDTA acid,Citric Acid

                            Therapeutic Area : Podiatry

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kane Biotech Announces FDA 510(k) Clearance for its coactiv+™ Antimicrobial Wound Gel

                            Details : coactiv+ Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult pop...

                            Product Name : coactiv+

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 25, 2023

                            Lead Product(s) : EDTA acid,Citric Acid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            MiMedx

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            MiMedx

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Amnion Membrane Allograft

                            Therapeutic Area : Podiatry

                            Study Phase : Approved

                            Sponsor : Gunze Medical Limited

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            MIMEDX Announces Commercial Launch of EPIFIX® in Japan with Exclusive Distribution Agreement with Gunze Med...

                            Details : EPIFIX (human amnion membrane allograft) is a PURION® processed placental tissue allograft that supports the healing cascade by providing a semi-permeable, protective barrier over wounds.

                            Product Name : Epifix

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 04, 2023

                            Lead Product(s) : Human Amnion Membrane Allograft

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved

                            Sponsor : Gunze Medical Limited

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            MiMedx

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            MiMedx

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Amnion Membrane Allograft

                            Therapeutic Area : Podiatry

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MIMEDX EPIFIX® Receives Reimbursement Approval in Japan

                            Details : EPIFIX (Human Amnion-chorion Membrane Allograft) is a PURION® processed placental tissue allograft that supports the healing cascade by providing a protective barrier over wounds.

                            Product Name : Epifix

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 12, 2022

                            Lead Product(s) : Human Amnion Membrane Allograft

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Centaur Pharmaceuticals

                            India arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Centaur Pharmaceuticals

                            India arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diperoxochloric Acid

                            Therapeutic Area : Podiatry

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Centaur Pharma Launches Novel Topical Solution WoxHeal for the Treatment of Diabetic Foot Ulcer

                            Details : WOXheal has dual mechanism of action, i.e. it has functional antibacterial action against Gram positive and gram negative bacteria and it also promotes growth of fibroblast cells, thereby yielding complete wound closure.

                            Product Name : WOXheal

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 08, 2020

                            Lead Product(s) : Diperoxochloric Acid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth